A5103139235- COVID-19 Clinical Research Studies
- Vibrio bacteria research studies
- Eosinophilic Disorders and Syndromes
- SARS-CoV-2 and COVID-19 Research
- Antibiotic Resistance in Bacteria
- Sustainable Supply Chain Management
- Antibiotic Use and Resistance
- Environmental Sustainability in Business
- Skin Diseases and Diabetes
- Nosocomial Infections in ICU
- Methemoglobinemia and Tumor Lysis Syndrome
- Environmental Education and Sustainability
- Muscle and Compartmental Disorders
- COVID-19 Impact on Reproduction
- Inflammatory Myopathies and Dermatomyositis
- Long-Term Effects of COVID-19
- Intensive Care Unit Cognitive Disorders
- COVID-19 and healthcare impacts
Aga Khan University
2012-2023
Superior University
2023
Aga Khan University Hospital
2015-2020
Meplazumab, a humanized CD147 antibody, has shown favourable safety and efficacy in our previous clinical studies. In DEFLECT (NCT04586153), 167 patients with severe COVID-19 were enroled randomized to receive three dosages of meplazumab placebo. Meplazumab at 0.12 mg/kg, compared the placebo group, showed benefits significantly reducing mortality by 83.6% (2.4% vs. 14.6%, p = 0.0150), increasing proportion alive discharged without supplemental oxygen (82.9% 70.7%, 0.0337) who achieved...
Introduction Cytokine release syndrome in COVID-19 is characterized by hyperinflammation, which manifests as acute respiratory distress (ARDS), multiorgan failure, and high inflammatory parameters. Tocilizumab, an interleukin 6 (IL-6) antagonist has been used ARDS with conflicting results from different parts of the world. Objective To study treatment outcomes tocilizumab patients hyperinflammation using World Health Organization (WHO) ordinal scale. Methods An observational was conducted...
Background: Acinetobacter baumannii is a source of nosocomial infections in many hospitals and has been associated with pneumonia, bacteremia, wound infections, urinary tract meningitis published data. Studies have shown that prognosis varies the site infection. The rationale this study to determine if respiratory infection C-MRAB higher mortality as compared non-respiratory it prognostic therapeutic implications. Methods: A prospective cohort 60 patients acinetobacter infection, 30 each...
Abstract Background: Extended spectrum β-lactamases (ESBL) producing Enterobacteriaceae predominantly E. coli and K. pneumonia bacteremia have limited treatment options high mortality. Objective: To determine the risk factors for in-hospital mortality particularly with Carbapenem versus Beta lactam/beta lactamase combination (BL/BLI) in patients Ceftriaxone resistant bacteremia. Methods: A retrospective descriptive study was conducted at Aga Khan University, Karachi, Pakistan. Adult...
Introduction: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred initially in December 2019 the city Wuhan, Hubei province, China where patients mainly presented with respiratory symptoms. In Pakistan first case was identified on February 26, 2020 and since then Aga Khan University Karachi is at forefront fight against COVID-19. After receiving all required approvals, this trial undertaken to determine safety efficacy transfusing Convalescent Plasma...